Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of...

Full description

Bibliographic Details
Main Authors: Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Molecular Sciences
Subjects:
SGLT2 inhibitors
cardiac protection
autophagy
innate immunity
Online Access:https://www.mdpi.com/1422-0067/22/13/7170

Internet

https://www.mdpi.com/1422-0067/22/13/7170

Similar Items